UroGen Pharma (FRA:UR8) Tariff Resilience Score: 6/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR8 UroGen Pharma Ltd FRA:UR8
60 GF Score
Price €34.31
GF Value €17.92
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Tariff Resilience Score?

UroGen Pharma FRA:UR8 +1.18% 60 Tariff Resilience Score is 6 as of Jul. 21, 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €17.92 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,370 Biotechnology companies, UroGen Pharma ranks better than 75.99% on this metric.

UroGen Pharma has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

UroGen Pharma has UroGen Pharma relies on international suppliers for raw materials but has a strong U.S. market presence. While past tariffs have affected costs, the company has some pricing power and can explore alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes UroGen Pharma might have Average Resilient.

UroGen Pharma  (FRA:UR8) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

UroGen Pharma Tariff Resilience Score Related Terms

FRA:UR8 vs SEPN, FTRE, MLTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, UroGen Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Tariff Resilience Score falls into.


FRA:UR8
60GF Score
UroGen Pharma Ltd FRA:UR8
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
UroGen Pharma (FRA:UR8) has a Tariff Resilience Score of 6 as of Jul. 21, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, UroGen Pharma ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is UroGen Pharma's Tariff Resilience Score too high?
UroGen Pharma's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. UroGen Pharma's value of 6 is 50% above this industry median. Based on the distribution chart, UroGen Pharma ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Tariff Resilience Score compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #329 out of 1370 companies for Tariff Resilience Score. This places UroGen Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. UroGen Pharma's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.92, compared to a current price of €34.31 — trading 91.5% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Tariff Resilience Score is 6 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €34.31 is trading 91.5% above its estimated GF Value™ of €17.92. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Tariff Resilience Score: 6
  • GF Value™: €17.92 vs. price of €34.31 (91.5% above fair value)
  • GF Score™: 60/100 with 10 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score

Get the complete analysis for FRA:UR8

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.31
Price
€17.92
GF Value